中文摘要：

目的评价DC-CIK作为效应细胞对肿瘤细胞的杀伤作用，探讨DC＋CIK治疗卵巢癌的可行性。方法无菌条件下抽取外周血100mL，分离、培养树突状细胞（DC）和诱导性杀伤细胞（CIK），细胞培养10天后，第一天输注给患者2×10＋个Dc细胞，第二天输注2×10＋个CIK细胞，第三天输注2X10＋个CIK细胞，每个月1次，连续治疗3个月，治疗后根据实体瘤疗效评价标准（RECIST）评价疗效，通过QLQ。c30量表对治疗前后生命质量进行评估。结果（1）患者生命质量：总体健康、躯体功能、情绪功能、症状领域、失眠及食欲丧失在治疗后均得到改善；（2）免疫功能：T淋巴细胞（CD3＋）、辅助性T细胞（CD3＋CD4＋）、自然杀伤细胞（NK）均有所升高，抑制性T细胞（CD3＋CD8＋）下降；（3）肿瘤标记物：糖类抗原CAl25和CAl53水平降低。结论DC。CIK生物疗法对于卵巢癌晚期患者是有效和安全的，能够改善患者生活质量，提高患者免疫功能，降低肿瘤标志物且无毒副作用。

英文摘要：

ABSTRACT Objective To evaluate the killing effect of DC-CIK cells, as the effector cell, on tumor cells and to discuss the feasibility of DC-CIK cells in the treatment of ovarian cancer. Methods Under sterile condition, 100 mL of peripheral blood was drawn from the patient, and then isolated and cultured for dendritic cells （DC） and cytokin-in- dueed killers （CIK） for 10 days; on the first day after the 10-day culture, DC cells （2 x 107） were infused into the patient; on the second and third day, CIK cells （2 x 109） was infused into the patient respectively; the procedure went once a month and kept in continuation for 3 months; RECIST （Response Evaluation Criteria in Solid Tumors） was applied in the evaluation of curative effect while QLQ-C30 Scale was applied in the assessment of the quality of life after treatment. Results After treatment, great improvement was found in general health, physical function, emotional function, symptoms, insomnia and appetite loss ; the levels of T lymphocytes （ CD3 ＋ ）, T helper cells （ CD3 ＋ CD4 ＋ ） and natural killer （NK） cells increased while that of T cells （CD3 ＋ CD8 ＋ ） decreased; the levels of carbohydrate an- tigen 125 （CA125） and carbohydrate antigen 153 （CA153） both dropped down. Conclusions DC-CIK biotherapy is effective and safe for patients with advanced ovarian cancer, it can improve the quality of life, enhance immunity of the oatients, reduces tumor markers and has non-toxic side effects.